FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.65 USD
-0.18 (-2.71%)
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
73.35M
34.71M
29.75M
10.65M
Annual Depreciation
2.34M
2.37M
2.97M
3.33M
Capital Expenditure
-17.95M
-9.06M
-2.13M
-750k
Net PPE
88.96M
41.4M
28.9M
8.07M
All figures are in USD.
